A5034390644- Hepatitis C virus research
- HIV/AIDS drug development and treatment
- HIV Research and Treatment
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
- Systemic Lupus Erythematosus Research
- HIV/AIDS Research and Interventions
- Chronic Lymphocytic Leukemia Research
- Immunodeficiency and Autoimmune Disorders
- Stellar, planetary, and galactic studies
- Astro and Planetary Science
- Viral-associated cancers and disorders
- T-cell and Retrovirus Studies
- Monoclonal and Polyclonal Antibodies Research
- Immune Cell Function and Interaction
- Lymphoma Diagnosis and Treatment
- Cytomegalovirus and herpesvirus research
- Biochemical and Molecular Research
- Blood groups and transfusion
- Nuclear physics research studies
- Parvovirus B19 Infection Studies
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Biological Research and Disease Studies
- Astronomy and Astrophysical Research
Janssen (United States)
2012-2016
Janssen (Belgium)
2012-2015
Janssen (Switzerland)
2015
Ortho Clinical Diagnostics (United States)
2003-2015
Kyushu University
2013
Scripps Research Institute
1997-2011
Scripps Clinic
2002-2011
Vertex Pharmaceuticals (United States)
2011
Merck & Co., Inc., Rahway, NJ, USA (United States)
2011
University of Pittsburgh at Titusville
2011
Up to 60% of patients with hepatitis C virus (HCV) genotype 1 infection do not have a sustained virologic response therapy peginterferon alfa plus ribavirin.
Nonnucleoside reverse transcriptase inhibitors (NNRTIs) have proven efficacy against human immunodeficiency virus type 1 (HIV-1). However, in the setting of incomplete viral suppression, efavirenz and nevirapine select for resistant viruses. The diarylpyrimidine etravirine has demonstrated durable patients infected with NNRTI-resistant HIV-1. A screening strategy used to test NNRTI candidates from same series as identified TMC278 (rilpivirine). is an showing subnanomolar 50% effective...
Hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Studies HCV replication pathogenesis have so far been hampered by the lack an efficient tissue culture system for propagating in vitro. Although primarily hepatotropic virus, increasing body evidence suggests that also replicates extrahepatic tissues natural infection. In this study, we established B-cell line (SB) from HCV-infected non-Hodgkin's lymphoma. RNA proteins were...
Hepatitis C virus (HCV) RNA detection, viral load quantification, and HCV genotyping are widely used in clinical practice. Recently, the availability of an anticore antigen (Ag) monoclonal antibody allowed development enzyme-linked immunosorbent assay (ELISA) detecting quantifying total core Ag peripheral blood HCV-infected patients. The aims present study were to investigate biologic significance this new marker infection, establish intrinsic performance current assay, determine its...
To evaluate the efficacy, safety and virologic resistance profile of etravirine (TMC125), a next-generation nonnucleoside reverse transcriptase inhibitor, over 48 weeks in treatment-experienced adults infected with HIV-1 strains resistant to inhibitor other antiretrovirals.DUET-1 (NCT00254046) DUET-2 (NCT00255099) are two identically designed, randomized, double-blind phase III trials.Patients received twice-daily 200 mg or placebo, each plus background regimen darunavir/ritonavir,...
Objective: To refine the genotypic and phenotypic correlates of response to nonnucleoside reverse transcriptase inhibitor etravirine. Design: Initial analyses identified 13 etravirine resistance-associated mutations (RAMs) clinical cutoffs (CCOs) for A multivariate analysis was performed initial RAM list improve predictive value resistance testing with regard virologic relationship data. Methods: Week 24 data were pooled from phase III studies TMC125 Demonstrate Undetectable viral load in...
view Abstract Citations (181) References (57) Co-Reads Similar Papers Volume Content Graphics Metrics Export Citation NASA/ADS S-Process Nucleosynthesis: Classical Approach and Asymptotic Giant Branch Models for Low-Mass Stars Kaeppeler, F. ; Gallino, R. Busso, M. Picchio, G. Raiteri, C. A critical comparison is made between the results of s-process nucleosynthesis obtained with phenomenological classical approach a stellar model helium shell burning in low-mass stars. For first time, close...
Genotypic and phenotypic characterization was performed of HIV-1 isolates from treatment-naive HIV-1-infected patients experiencing virologic failure (VF) during treatment with the nonnucleoside reverse transcriptase inhibitor (NNRTIs) rilpivirine or efavirenz in pooled phase 3 studies ECHO THRIVE. Among 686 receiving rilpivirine, 72 (10%) experienced VF versus 39 682 (6%) efavirenz. In low baseline viral load (VL) ≤100,000 copies per milliliter, proportions VFs (19 368) (16 330) were same...
Background. Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples from patients in phase 3 trials determine frequency and retention variants who did not achieve sustained virologic response (SVR).
The resistance profile of darunavir (TMC114) in treatment-experienced patients was explored using pooled week 24 data from POWER 1, 2, and 3 at the recommended dose with low-dose ritonavir (darunavir/r, 600/100 mg bid, N = 458). Baseline fold change EC50 a strong predictor virological response 24. Preliminary phenotypic clinical cut-offs 10 40 were established. Virological to darunavir/r maintained presence baseline high number IAS-USA PI resistance-associated mutations (IAS-USA RAMS);...
ABSTRACT The prevalence of naturally occurring hepatitis C virus (HCV) variants that are less sensitive to direct-acting antiviral (DAA) inhibitors has not been fully characterized. We used population sequence analysis assess the frequency such in plasma samples from 3,447 DAA-naive patients with genotype 1 HCV. In general, HCV lower-level resistance (3- 25-fold increased 50% inhibitor concentration [IC 50 ]) telaprevir were observed as dominant species 0 3% patients, depending on specific...
Background & AimsSimeprevir is an oral hepatitis C virus (HCV) NS3/4A protease inhibitor approved for treatment of chronic HCV infection. Baseline NS3 polymorphisms in all patients and emerging mutations who failed to achieve sustained virologic response (SVR) with simeprevir plus peginterferon/ribavirin (PR) Phase IIb/III studies are described.MethodsBaseline sequencing data were available 2007 genotype 1 (GT1)-infected patients. Post-baseline 197/245 simeprevir-treated did not SVR. In...
ABSTRACT The natural ligands for the CCR5 chemokine receptor, macrophage inflammatory protein 1α (MIP-1α), MIP-1β, and RANTES (regulated on T-cell activation, normal expressed secreted), are known to inhibit human immunodeficiency virus (HIV) entry, N-terminally modified analogues more potent than native in blocking infection. However, agents may select HIV-1 variants that use alternative coreceptors at less fully inhibitory concentrations. In this study, two N-terminal chemical...
view Abstract Citations (124) References (40) Co-Reads Similar Papers Volume Content Graphics Metrics Export Citation NASA/ADS S-Process Nucleosynthesis in Massive Stars and the Weak Component. II. Carbon Burning Galactic Enrichment Raiteri, C. M. ; Busso, Gallino, R. Picchio, G. The s-process that occurs shell carbon-burning phase of a typical massive star 25 solar masses is examined. It shown neutron captures during C-burning can significantly change s-abundances. composition s-processed...
Background In patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared PR alone. However, genotypic changes could be observed TVR-treated who did not achieve an SVR. Methods Population sequence analysis of the NS3•4A region was performed SVR TVR-based treatment. Results Resistant variants were after treatment a telaprevir-based regimen 12% treatment-naïve...
The registrational phase III clinical trials of the nonnucleoside reverse transcriptase (RT) inhibitor (NNRTI) rilpivirine (RPV) in combination with two nucleoside/nucleotide RT inhibitors (NRTIs) found a unique genotypic resistance pattern involving NNRTI mutation E138K NRTI M184I. Eighty percent subjects used emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF); single tablet regimen FTC/RPV/TDF is development.HIV-1 and/or M184V or I mutations were constructed phenotyped MT-2 cells...